1. Home
  2. RVPH vs MULN Comparison

RVPH vs MULN Comparison

Compare RVPH & MULN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RVPH
  • MULN
  • Stock Information
  • Founded
  • RVPH 2006
  • MULN 2014
  • Country
  • RVPH United States
  • MULN United States
  • Employees
  • RVPH N/A
  • MULN N/A
  • Industry
  • RVPH Biotechnology: Pharmaceutical Preparations
  • MULN Auto Manufacturing
  • Sector
  • RVPH Health Care
  • MULN Consumer Discretionary
  • Exchange
  • RVPH Nasdaq
  • MULN Nasdaq
  • Market Cap
  • RVPH 36.4M
  • MULN 32.6M
  • IPO Year
  • RVPH N/A
  • MULN N/A
  • Fundamental
  • Price
  • RVPH $1.20
  • MULN $1.85
  • Analyst Decision
  • RVPH Strong Buy
  • MULN
  • Analyst Count
  • RVPH 3
  • MULN 0
  • Target Price
  • RVPH $14.33
  • MULN N/A
  • AVG Volume (30 Days)
  • RVPH 160.2K
  • MULN 1.7M
  • Earning Date
  • RVPH 08-12-2024
  • MULN 08-12-2024
  • Dividend Yield
  • RVPH N/A
  • MULN N/A
  • EPS Growth
  • RVPH N/A
  • MULN N/A
  • EPS
  • RVPH N/A
  • MULN 2821.15
  • Revenue
  • RVPH N/A
  • MULN $399,335.00
  • Revenue This Year
  • RVPH N/A
  • MULN N/A
  • Revenue Next Year
  • RVPH N/A
  • MULN N/A
  • P/E Ratio
  • RVPH N/A
  • MULN $0.00
  • Revenue Growth
  • RVPH N/A
  • MULN N/A
  • 52 Week Low
  • RVPH $1.05
  • MULN $1.80
  • 52 Week High
  • RVPH $6.80
  • MULN $153.00
  • Technical
  • Relative Strength Index (RSI)
  • RVPH 39.64
  • MULN 24.87
  • Support Level
  • RVPH $1.14
  • MULN $2.15
  • Resistance Level
  • RVPH $1.35
  • MULN $2.20
  • Average True Range (ATR)
  • RVPH 0.10
  • MULN 0.16
  • MACD
  • RVPH 0.03
  • MULN 0.02
  • Stochastic Oscillator
  • RVPH 50.00
  • MULN 6.49

About RVPH Reviva Pharmaceuticals Holdings Inc.

Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and its other drug candidate is RP1208.

About MULN Mullen Automotive Inc.

Mullen Automotive Inc is engaged in manufacturing electric vehicles and energy solutions. The company strives to make electric vehicles more accessible by building an end-to-end ecosystem that takes care of all aspects of electric vehicle ownership. The Company owns and partners with several synergistic businesses, all working towards the same goal of creating clean and scalable electric vehicles and energy solutions. The company has two segments Bollinger and Mullen/ELMS, which generates revenue.

Share on Social Networks: